Therapeutic compositions comprising imidazole and imidazolium compounds
View Patent ↗Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.
1. A method of treating musculoskeletal pain comprising orally administering a pharmaceutical composition to a mammal in need thereof, wherein the pharmaceutical composition comprises:
in an amount that is less than 0.1% w/w, and greater than 0%; or
in an amount that is less than 0.1% w/w, and greater than 0% w/w;
wherein any amount in % w/w is based upon the total weight of Compound A, Compound B, and Compound C;
wherein each A is independently an acidic functional group.
2. The method of claim 1 , wherein the musculoskeletal pain comprises back pain, pain in extremity, joint pain, or muscle pain.
3. A method of treating joint pain not associated with cancer comprising orally administering a pharmaceutical composition to a human being suffering from joint pain not associated with cancer, wherein the pharmaceutical composition comprises:
a) zoledronic acid; or
b) one of the following:
1) zoledronic acid and
in an amount that is less than 0.1% w/w and greater than 0% w/w;
2) zoledronic acid and
in an amount that is less than 0.1% w/w and greater than 0% w/w; or
3) zoledronic acid and a combination of Compound 1 in an amount that is less than 0.1% w/w and greater than 0% w/w, and Compound 2 in an amount that is less than 0.1% w/w and greater than 0% w/w;
wherein the pharmaceutical composition is free of therapeutically active agents that are not zoledronic acid, Compound 1, and Compound 2;
wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2; and
wherein the bioavailability of zoledronic acid in the dosage form is about 1.1% to about 4%.
4. The method of claim 3 , wherein the pharmaceutical composition is administered in an amount and frequency that results in an AUC of zoledronic acid, over a four week period, that is about 100 ng·h/mL to about 2000 ng·h/mL.
5. The method of claim 3 , wherein the pharmaceutical composition is administered in an amount that results in an AUC of zoledronic acid, over a twenty-four hour period, that is about 20 ng·h/mL to about 500 ng·h/mL.
6. The method of claim 3 , wherein the joint pain is located in the back.
7. The method of claim 6 , wherein the pharmaceutical composition is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.
8. The method of claim 3 , wherein the joint pain comprises pain in an extremity.
9. The method of claim 8 , wherein the pharmaceutical composition is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.
10. The method of claim 3 , wherein the pharmaceutical composition is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.
11. A method of treating complex regional pain syndrome comprising orally administering a pharmaceutical composition to a human being suffering from complex regional pain syndrome, wherein the pharmaceutical composition comprises:
a) zoledronic acid; or
b) one of the following:
1) zoledronic acid and
in an amount that is less than 0.1% w/w and greater than 0% w/w;
2) zoledronic acid and
in an amount that is less than 0.1% w/w and greater than 0% w/w; or
3) zoledronic acid and a combination of Compound 1 in an amount that is less than 0.1% w/w and greater than 0% w/w, and Compound 2 in an amount that is less than 0.1% w/w and greater than 0% w/w;
wherein the pharmaceutical composition is free of therapeutically active agents that are not zoledronic acid, Compound 1, and Compound 2;
wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2; and
wherein the bioavailability of zoledronic acid in the dosage form is about 1.1% to about 4%.
12. The method of claim 11 , wherein the pharmaceutical composition is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.
13. The method of claim 11 , wherein the pharmaceutical composition is administered in an amount and frequency that results in an AUC of zoledronic acid, over a four week period, that is about 100 ng·h/mL to about 2000 ng·h/mL.
14. The method of claim 11 , wherein the pharmaceutical composition is administered in an amount that results in an AUC of zoledronic acid, over a twenty-four hour period, that is about 20 ng·h/mL to about 500 ng·h/mL.
15. A method of treating ankylosing spondylitis comprising orally administering a pharmaceutical composition to a human being suffering from ankylosing spondylitis, wherein the pharmaceutical composition comprises:
a) zoledronic acid; or
b) one of the following:
1) zoledronic acid and
in an amount that is less than 0.1% w/w and greater than 0% w/w;
2) zoledronic acid and
in an amount that is less than 0.1% w/w and greater than 0% w/w; or
3) zoledronic acid and a combination of Compound 1 in an amount that is less than 0.1% w/w and greater than 0% w/w, and Compound 2 in an amount that is less than 0.1% w/w and greater than 0% w/w;
wherein the pharmaceutical composition is free of therapeutically active agents that are not zoledronic acid, Compound 1, and Compound 2;
wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2; and
wherein the bioavailability of zoledronic acid in the dosage form is about 1.1% to about 4%.
16. The method of claim 15 , wherein the pharmaceutical composition is administered in an amount such that a monthly dose of zoledronic acid is about 1 mg to about 600 mg.
17. The method of claim 15 , wherein the pharmaceutical composition is administered in an amount and frequency that results in an AUC of zoledronic acid, over a four week period, that is about 100 ng·h/mL to about 2000 ng·h/mL.
18. The method of claim 15 , wherein the pharmaceutical composition is administered in an amount that results in an AUC of zoledronic acid, over a twenty-four hour period, that is about 20 ng·h/mL to about 500 ng·h/mL.
19. The method of claim 3 , wherein the bioavailability of zoledronic acid in the dosage form is from about 1.1% to about 3%.
20. The method of claim 11 , wherein the bioavailability of zoledronic acid in the dosage form is from about 1.1% to about 3%.
21. The method of claim 15 , wherein the bioavailability of zoledronic acid in the dosage form is from about 1.1% to about 3%.